Universal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 18,830 shares of the company’s stock, valued at approximately $224,000.

Other hedge funds also recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Nurix Therapeutics in the 4th quarter valued at about $28,000. Aquatic Capital Management LLC acquired a new position in Nurix Therapeutics during the fourth quarter worth approximately $87,000. Summit Investment Advisors Inc. lifted its stake in Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company’s stock valued at $138,000 after buying an additional 877 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Nurix Therapeutics in the fourth quarter valued at approximately $164,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Nurix Therapeutics by 38.9% in the first quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company’s stock valued at $109,000 after acquiring an additional 2,562 shares during the period.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,402 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $11.03, for a total transaction of $59,584.06. Following the transaction, the chief financial officer directly owned 35,512 shares in the company, valued at approximately $391,697.36. This represents a 13.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gwenn Hansen sold 4,308 shares of the stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total transaction of $51,739.08. Following the completion of the transaction, the insider directly owned 69,023 shares of the company’s stock, valued at approximately $828,966.23. This trade represents a 5.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,014 shares of company stock valued at $163,014 in the last quarter. Insiders own 7.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $27.00 target price on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of Nurix Therapeutics in a research report on Thursday, July 31st. HC Wainwright reduced their target price on shares of Nurix Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a report on Monday, July 14th. Wall Street Zen upgraded shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 21st. Finally, Stephens restated an “overweight” rating and issued a $30.00 price target on shares of Nurix Therapeutics in a research report on Thursday, July 10th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, Nurix Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $28.87.

Nurix Therapeutics Price Performance

NRIX opened at $11.28 on Tuesday. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56. The stock has a market capitalization of $862.36 million, a P/E ratio of -4.32 and a beta of 2.14. The business has a 50 day simple moving average of $11.85 and a 200-day simple moving average of $12.93.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.27. Nurix Therapeutics had a negative return on equity of 45.26% and a negative net margin of 234.57%. The firm had revenue of $44,056 billion during the quarter, compared to analysts’ expectations of $16.26 million. Research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.